Breast cancer checks missing most women under 50 who are at risk, says study — SkimNews
SkimNews Take
Using family history as the primary screening heuristic implicitly assumes heredity drives most cases, yet the 95% miss rate reveals the criterion functions as a convenient proxy rather than a true risk indicator — the barrier is deployment, not discovery.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- NICE guidelines for breast cancer screening under-50s miss up to 95% of those at higher risk because the criteria rely solely on inherited genes rather than lifestyle factors, according to a study in the British Journal of Cancer.
- The Cambridge/ICR team used the Boadicea risk calculator—combining family history, lifestyle, reproductive history, and genetic information—and identified 8 times as many women under 50 who developed breast cancer compared to current NICE criteria.
- Under the Boadicea tool, 26.5% of women under 50 would be referred for further assessment, capturing 34.8% of those who develop breast cancer within a decade, versus just 1.4% referred and 4.4% captured under current NICE criteria.
- 73% of women under 50 who develop breast cancer within a decade have no family history of the disease—the key criterion NICE uses to flag extra assessment.
- Lead researcher Dr Juliet Usher-Smith said the NHS should review the criteria, while acknowledging that more referrals would add to workloads and could cause unnecessary anxiety and checks.
- NICE said it welcomed the findings and recognized the potential of multifactorial risk tools but maintained current evidence does not warrant a change to its breast cancer guidelines.
- The UK invites women for screening starting at age 50 every three years, while Sweden begins at 40, and Australia and Canada screen every two years; breast cancer is a leading cause of death in UK women under 50.
Why it matters: NICE's family-history-only criteria capture 4.4% of under-50 breast cancer cases, while a broader tool identifies 34.8%—yet NICE says current evidence doesn't justify a change. The gap leaves the 73% of under-50 patients without family history—like Natasha Finch, diagnosed at 23 with no risk factors—dependent on self-advocacy rather than systematic screening.
Ask SkimNews
